NYSE:DGXHealthcare
Quest Diagnostics MRD Blood Test May Support Growth In Higher Value Oncology
Quest Diagnostics (NYSE:DGX) has introduced a blood based minimal residual disease test for multiple myeloma that uses advanced flow cytometry.
The company reports that the assay offers sensitivity comparable to next generation sequencing with a lower expected cost and less invasive sampling.
FDA draft guidance recognizes minimal residual disease as an endpoint in multiple myeloma clinical trials, supporting broader use of MRD testing in research.
For you as an investor, this development...